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Abstract
Postpartum hemorrhage (PPH) is the leading cause of maternal death. In developing 
countries, approximately 8% of maternal death is caused by PPH. Protocols should pro-
vide a standardized approach to evaluate and monitor the patients. A standard  protocol 
must be recognized by the institution and must be accepted and known by all team mem-
bers. Additionally, it is important to have a massive obstetric hemorrhage protocol (red 
code) for those patients with an important bleeding who require blood products available 
as soon as possible. In the red code activation protocol there are several key points to 
consider: the management algorithm must be known and accepted by all team members, 
a clear and effective communication between the team must be established and all the 
participants must know the role they play. Massive obstetric hemorrhage has a multi-
disciplinary implication: obstetricians, anesthesiologists, pediatricians, midwife, nurses, 
auxiliary staff, and laboratory blood bank staff. The active participation of the multidisci-
plinary team in simulations before the protocols implementation facilitates the evaluation 
of critical points and subsequent changes before their final application, the assessment of 
the adequacy of circuits and infrastructure, as well as a better protocols compliance.
Keywords: postpartum hemorrhage, red code, massive blood transfusion, protocol,  
multi-professional simulation training
1. Introduction
Postpartum hemorrhage (PPH) is commonly defined as a blood loss of 500 ml or more within 
24 h after birth, whereas major PPH is defined as a blood loss of 1000 ml or more within the 
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same time frame. Major PPH can be further subdivided into moderate (1001–2000 ml) and 
severe (more than 2000 ml). Secondary PPH is defined as abnormal or excessive bleeding from 
the birth canal between 24 h and 12 weeks postnatally [1]. The quantification of postpartum 
blood loss is a subjective parameter that hinders the application of this definition and usually 
there is an underestimation of the loss.
It has recently been proposed to define PPH as a blood loss that may lead to hemodynamic 
instability [2].
2. Epidemiology
PPH affects approximately 2% of all women who gave birth: it is associated not only with 
nearly one quarter of all maternal deaths globally (around 125,000 deaths per year), but is also 
the leading cause of maternal mortality in low-income countries. PPH is the primary cause of 
nearly one quarter of all maternal deaths globally. PPH is a significant contributor long-term 
disability as well as to a number of other severe maternal conditions generally associated with 
more substantial blood loss, including shock and organ dysfunction [3].
Maternal collapse rate due to major PPH lies somewhere between 0.14 and 6/1000 (14 and 
600/100,000) births [4].
3. Etiology of PPH
The causes of PPH can be simplified under the acronym “4T”: tone (atony), trauma (trauma 
of the birth canal), tissue (retention of remains), and thrombin (clotting disorders). Multiple 
predisposing factors can be related to these causes (Table 1).
The assessment of antenatal risk factors predicts only 40% of PPH cases, with placenta praevia 
and placenta accreta being the most important identifiable risk factors for severe bleeding. 
Therefore, 60% of PPHs occur in women with unknown risk factors. Before a primary PPH, 
a correct etiological diagnosis will be important, since the management will depend on the 
cause of the hemorrhage.
4. Prevention
Uterine atony is the most common cause of PPH, since it accounts for 80% of it. Therefore, the 
most effective preventive measure is the active management of the third phase of delivery, 
which has been shown to reduce PPH by 60% of cases, a significant reduction in postpartum 
anemia and the need for transfusion [5].
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The current definition of active management of the third phase of delivery proposed by the 
World Health Organization (WHO) includes the administration of uterotonics, late cord 
clamping, and controlled cord traction to obtain the placenta. The uterine massage does not 
offer benefits in the prophylaxis of PPH, but in the treatment [3].
4T's Etiology Risk factor
Tone Overdistension Multiple pregnancy
Fetal macrosomia
Polyhydramnios
Fetal congenital defects
Hydrocephalus
Muscle fatigue Prolonged labor
Multiparity
Infection
Chorioamnionitis
Prolonged PROM
Fever
Tocolytic drugs Betamimetics
Nifedipine
SO
4
Mg
Anesthetics
Trauma Laceration of cervix, vagina, or 
perineum
Instrumental delivery
Episiotomy
Injury during cesarean section Malpresentation
Fetal intrauterine manipulation
Advanced Hodge line presentation
Uterine rupture Previous uterine surgery
Uterine inversion Fundal placental implantation
Excessive cord traction
Multiparity
Tissue Retained placental products Previous uterine surgery
Placental abnormalities (placenta 
accreta, increta, percreta)
Placenta abruption
Placenta praevia
Thrombin Congenital coagulation disorders Hemophilia
Von Willebrand disease
Acquired coagulopathy Placental abruption
Pre-eclampsia
Sepsis
Amniotic fluid embolism
DIC
Hyperfibrinolysis
Pharmacologic anticogulation
Table 1. Postpartum hemorrhage etiology.
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Most PPHs occur during or immediately after delivery, but a significant proportion of them 
occur during the first few hours postpartum, so it is necessary to maintain prevention for a 
few hours. Therefore, it is necessary to use uterotonic drugs with long half-life or forms of 
administration that maintain the effect during these hours.
The first-line drug is oxytocin, the most effective treatment with fewer side effects [6]. The 
appropriate dose is 3–5 IU in slow bolus for 1–2 min to avoid undesirable effects or 10 IU 
intramuscularly. Its administration should start with the output of the anterior shoulder, just 
after birth or upon exiting the placenta. Because of its short half-life (10–15 min), it is recom-
mended to maintain continuous oxytocin infusion for about 4 h.
Carbetocin is a synthetic analog of oxytocin whose principal advantage is its longer half-
life compared with oxytocin (40 min vs. 10–15 min). It has the same side effects and its main 
indication is the prevention, not the treatment of PPH in elective cesarean sections. The 
appropriate dose is 100 μg by slow intravenous route. The scientific evidence has shown 
no differences in the prevention of PPH, only an improvement in relation to the use of 
additional uterotonics [7].
The use of ergometrine 0.2 mg intramuscularly is an alternative in cases of high risk of PPH. 
Although slightly more effective than oxytocin, because its half-life is 2–3 h, it has more side 
effects, especially the risk of hypertensive crisis in hypertensive patients. Its administration 
must be after the delivery of the placenta [8].
It can be considered as the use of misoprostol 400–600 μg orally or rectally, although it is less 
effective and has more effects than the previous ones, if no parenteral agents are ready for use 
or in settings where venous access, needles, or a refrigerator is not available [9].
Administration of tranexamic acid (0.5–1 g intravenously) appears to decrease blood loss 
following vaginal delivery and after cesarean delivery. In spite of this, more information is 
needed on its effectiveness and safety profile [10].
5. Maternal collapse
Maternal collapse is defined as an acute event involving the cardiorespiratory systems and/or 
brain, resulting in a reduced or absent conscious level (and potentially death), at any stage in 
pregnancy and up to 6 weeks after delivery [4].
The common reversible causes of collapse in any woman can be remembered using the well-
known ‘aide memoire’ employed by the Resuscitation Council of the 4 T's and the 4 H's 
(Table 2). In a pregnant woman, eclampsia and intracranial hemorrhage should be added to 
this list, and obstetric-specific causes are clearly more likely and must also be considered sys-
tematically. Owing to the lack of robust morbidity data regarding collapse, maternal deaths 
are often used as a reference point [4].
Hemorrhage is the most common cause of maternal collapse. Causes of major obstetric hemor-
rhage include postpartum hemorrhage, major antepartum hemorrhage from placenta praevia/
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accreta, placental abruption, uterine rupture, and ectopic pregnancy. In most cases of massive 
hemorrhage leading to collapse, the cause is obvious, but concealed hemorrhage should not 
be forgotten, including following cesarean section and ruptured ectopic pregnancy. Other 
rarer causes of concealed hemorrhage include splenic artery rupture and hepatic rupture. 
Blood loss is often underestimated; especially slow, steady bleeding and fit healthy women 
can tolerate significant loss prior to showing signs of decompensation.
5.1. Hypovolemic shock
Hypovolemic shock due to hemorrhage is defined as the blood loss that results in tissue hypo-
perfusion, with a maintained deficit of oxygen transport to tissues. The injury suffered by the 
organs marks the prognosis of bleeding, causing a disruption of metabolism and function of tis-
sues, which brings up metabolic acidosis and contributes to the development of coagulopathy.
6. Diagnosis
Clinical symptoms of hypovolemia may not be present until 10–20% of total whole blood 
volume is lost.
Reversible cause Cause in pregnancy
4H's Hypovolemia Bleeding (may be concealed) 
(obstetric/other) or relative 
hypovolemia of dense espinal block, 
septic or neurogenic shock
Hypoxia Pregnant patients can become 
hypoxic more quickly
Cardiac events: peripartum 
cardiomyopathy, myocardial 
infarction, aortic dissection, large-
vessel aneurysms
Hypo/hyperkalemia and other 
electrolyte disturbances
No more likely
Hypothermia No more likely
4T's Thromboembolism Amniotic fluid embolus, pulmonary 
embolus, air embolus, myocardial 
infarction
Toxicity Local anesthetic, magnesium, other
Tension pneumothorax Following trauma/suicide attempt
Tamponade (cardiac) Following trauma/suicide attempt
Eclampsia and pre-eclampsia Includes intracranial hemorrhage
Table 2. Reversible causes of maternal collapse.
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Hypovolemia can be recognized by tachycardia, diminished blood pressure, and the absence 
of perfusion as assessed by skin signs (skin turning pale) and/or capillary refill on forehead, 
lips, and nail beds. The patient may feel dizzy, faint, nauseated, or very thirsty. These signs 
are also characteristic of most types of shock.
Obvious signs of external bleeding should be noted while remembering that people can bleed 
to death internally without any external blood loss.
6.1. Stages of hypovolemic shock
Hypovolemic shock can be classified in four stages depending on its severity (Table 3).
6.2. Laboratory diagnosis
A single hemoglobin and hematocrit value is not useful for assessing bleeding and its sever-
ity. These parameters are poorly sensitive for the early detection of significant bleeding. 
However, the serial determinations of hemoglobin and hematocrit have very good specificity.
Lactate and pH are analytical parameters that are altered when the metabolism becomes anaero-
bic. They are sensitive measures to monitor the importance of bleeding and shock. A lactate lower 
than 22 mg/dL and a pH lower than 7.20 are indicators of hypoperfusion and tissue distress.
7. Management in major obstetric hemorrhage
Hemorrhage is the most common cause of maternal collapse and a consequence of other 
causes of collapse. There must be a high index of suspicion for bleeding and awareness of the 
limitations of clinical signs.
Stage 1 Stage 2 Stage 3 Stage 4
Blood loss Up to 15% (750 ml) 15–30% (750–1500 ml) 30–40% (1500–2000 
ml)
Over 40% (over 2000 
ml)
Blood pressure Normal (maintained 
by vasoconstriction)
Increased diastolic BP Systolic BP < 100 Systolic BP < 70
Heart rate Normal Slight tachycardia 
(>100 bpm)
Tachycardia (>120 
bpm)
Extreme tachycardia 
(>140 bpm) with 
weak pulse
Respiratory rate Normal Increased (>20) Tachypneic (>30) Extreme tachypnea
Mental status Normal Slight anxiety, 
restless
Altered, confused Decreased LOC, 
lethargy, coma
Skin Pallor Pale, cool, clammy Increased diaphoresis Extreme diaphoresis, 
mottling possible
Capillary refill Normal Delayed Delayed Absent
Urine output Normal 20–30 ml/h 20 ml/h Negligible
Table 3. Signs and symptoms of the major stages of hypovolemic shock.
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The management of PPH requires a multidisciplinary approach: midwifes and obstetric first-
line staff who must be awarded of important bleeding, senior obstetric staff, and anesthetist, 
that plays a crucial role in maintaining hemodynamic stability.
Communication with the patient and her birthing partner is crucial, and clear information 
about what is happening from the outset must be given.
There is limited evidence on appropriate intervention points and management strategies 
related to the hemostatic management of obstetric hemorrhage.
A primary survey of sever obstetric bleeding should follow a structured approach of simple 
“ABC”, including evaluation and resuscitation simultaneously.
7.1. A and B: assess airway and breathing
A high concentration of oxygen (10–15 l/min) should be administered, regardless of maternal 
oxygen concentration. Anesthetic assistance should be requested in case of impaired con-
sciousness [1].
7.2. C: evaluate circulation
Two intravenous lines must be taken and sent blood for diagnostic tests. Full blood count, 
coagulation, urea, electrolytes, and cross match must be evaluated [1].
Resuscitation management is based on both blood volume and oxygen-carrying capacity. 
Volume replacement must be undertaken on the basis that blood loss is often underestimated 
[11]. Compatible blood, supplied with the form of red cell concentrate (RCC), is the best fluid 
to replace major blood loss and should be transfused as soon as available, if necessary.
Resuscitation based on fluid replacement, blood transfusion, and drug therapy must be 
guided by hemodynamic goals, regardless of the moment it starts (Table 4).
7.3. Monitoring hemostasis
Routine coagulation tests are the most common methods for monitoring hemostasis during 
PPH, with the advantage of well-regulated quality control [12]. Their main drawback is that 
Goals Value
Arterial blood pressure 90–100 mmHg
Cardiac frequency <100 hb
Central venous pressure >6 mmHg
Cardiac index >2.5 l/min/m2
Serum lactate <2 mmol/l
pH >7.20
Table 4. Hemodynamic and analytic goals in resuscitation.
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they are too slow to be clinically useful in an acute and evolving situation. In addition, PT/
aPTT ratios have limited sensitivity to a developing coagulopathy associated with PPH, and 
are often normal, despite very large volumes of blood loss [13]. If laboratory-based tests are 
used, a Clauss fibrinogen must be measured rather than a PT-derived fibrinogen level.
Based on recent studies, point-of-care (POC) testing of coagulation using thromboelastogra-
phy or thromboelastometry (TEG® and ROTEM®) can provide early feedback to care provid-
ers about key changes in the maternal hemostatic profile during PPH. POC testing can be 
considered for rapid hemostatic assessment during PPH and these technologies have been 
endorsed in guidelines from the Obstetric Anaesthetists Association (UK) [14], the European 
Society of Anaesthesiology [15], and the American Society of Anaesthesiologists [16] (Table 5).
8. Fluid replacement
Fluid replacement is based on crystalloids and colloids. There have been no randomized con-
trolled trials comparing the use of colloids with other replacement fluids for resuscitation 
of women with PPH. There is indirect evidence from a Cochrane review that evaluated 78 
trials on the use of colloids in the resuscitation of critically ill patients who required volume 
replacement secondary to trauma, burns, surgery, sepsis, and other critical conditions. No 
evidence that resuscitation with colloids reduces the risk of death, compared to resuscitation 
with crystalloids was found [17]. Furthermore, the use of hydroxyethyl starch might increase 
mortality. And colloids are more expensive than crystalloids.
Based on the actual evidence, World Health Organization Guidelines recommend that intra-
venous fluid replacement in severe PPH must be with isotonic crystalloids in preference to 
colloids [18].
Rapid administration and warming of the infusion are essential issues in fluid therapy in 
severe PPH. But great amount of fluid replacement must be avoided because they can cause 
hemodilution and can deteriorate coagulopathy.
Immediate venepuncture for cross-match, full blood count, coagulation screen (and fibrinogen), renal and function 
liver for baseline
Monitor temperature every 15 min
Continuous pulse, blood pressure recording, and respiratory rate
Foley catheter to monitor urine output
Two peripheral cannulae (14G)
Consider arterial line monitoring
Consider transfer to a intensive therapy unit
Documentation of fluid balance, blood, blood products, and procedures
Table 5. Protocol for monitoring in major PPH.
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By consensus, total volume of 3.5 l of clear fluids (up to 2 l of warmed Hartmann's solution as 
rapidly as possible, followed by up to a further 1.5 l of warmed colloid if blood still not avail-
able) comprises the maximum that should be infused while awaiting compatible blood. The 
woman needs to be kept warm using appropriate measures.
9. Blood transfusion
9.1. Red cell concentrates and fresh frozen plasma
Transfusion rates have been increasing during recent years, likely due to the increases in rates 
of PPH [19]. Transfusion is an important indicator of severe obstetric morbidity and women 
who received four or more units of blood products should be reviewed [20].
The objective of resuscitation is to maintain hemoglobin at 9–10 mg/dl [21]. Early and rapid 
red cell concentrate (RCC) and fresh frozen plasma (FFP) transfusion in 1:1 rate (RCC: FFP) 
is the most recommended at the moment to improve hemostasis in severe PPH refractory to 
medical treatment [22].
If no hemostatic results are available and bleeding is continuing, then, after 4 units of red 
blood cells, FFP should be infused at a dose of 12–15 ml/kg until hemostatic test results are 
known [1].
The only strong recommendation on blood transfusion in PPH is that women receive RBCs as 
soon as possible in case of massive PPH. Because cross-matched blood is not always available, 
maternity units should have immediate access (within 5 min) to O-negative blood. If the need 
is less pressing, group-specific blood can be made available more quickly than fully cross-
matched blood. Consequently, all maternity units should have their own reserve of blood 
products if there is no blood bank on-site [23].
FFP is frequently issued as “shock packs” on an activation of major obstetric hemorrhage 
protocol. The objective is to maintain thrombin generation and fibrinogen by the replace-
ment of coagulation factors as early as possible. The disadvantage is that most women will 
have normal coagulation and platelets at the time of transfusion and will be receiving blood 
products with fewer fibrinogen and other coagulation factors than they have been circulating.
If no hemostatic tests are available, early FFP should be considered for conditions with a 
suspected coagulopathy, such as placental abruption or amniotic fluid embolism, or where 
detection of PPH has been delayed [1].
9.2. Platelets
Guidelines recommend that the platelet count should be kept more than 50,000/mm3 during 
active PPH and to achieve this, they should be infused when the count falls below 75,000/mm3 
[24]. Except for placental abruption, amniotic fluid embolus, severe preeclampsia, or inherited 
or immune thrombocytopenia, a platelet count less than 75,000/mm3 is uncommon during PPH.
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9.3. Fibrinogen
The clinician should be aware that fibrinogen normally increases during pregnancy; thus, 
normal ranges for nonpregnant adults often printed on hospital laboratory reports have little 
relevance to obstetrics. While a fibrinogen level in the immediate postpartum period <4 g/l is 
reassuring in terms of immediate clotting capacity, it is abnormal and should alert the clini-
cian to the presence of either significant blood loss or ongoing intravascular consumption. 
A fibrinogen level <3 g/l in a bleeding post-partum patient calls for preparation of both red 
cells and FFP or cryoprecipitate and, as outlined in this volume, a level of <2 g/l is generally 
considered an indication for component replacement [25].
The fibrinogen plasma level has been demonstrated to be a good predictor of PPH severity 
[26]. A fibrinogen plasma level of 2 g/l or less had a 100% positive predictive value for severe 
PPH [27]. Therefore, a plasma fibrinogen level of greater than 2 g/l should be maintained dur-
ing ongoing PPH.
Increasing the fibrinogen level by 1 g/l requires about 60 mg/kg fibrinogen [28], although if 
there is ongoing consumption or dilution, smaller increments would be expected [29]. The 
guidelines recommend fibrinogen concentrate use when fibrinogen is ≤1 g/l. Nevertheless, in 
an active bleeding is possible to start when fibrinogen is ≤1.5–2 g/l.
In the past, fibrinogen therapy was usually given as cryoprecipitate, but owing to the poten-
tial viral contamination and variable concentration of fibrinogen in cryoprecipitate, human 
plasma-derived fibrinogen concentrates are now available in most countries but not every-
where. Similar clinical outcomes and increments in fibrinogen have been reported for cryo-
precipitate and fibrinogen concentrates, but these are based on limited data [30].
Fibrinogen concentrate significantly reduced the need for massive transfusion of RBCs, 
plasma, and platelets [31]. Nevertheless, weak evidence supports the use of fibrinogen con-
centrate in bleeding patients [32] and there are currently some prospective, randomized stud-
ies investigating the role of fibrinogen concentrates in PPH [33, 34].
9.4. Prothrombin complex concentrate
Prothrombin complex concentrate contains clotting factors II, IX, and X ± VII and occasionally 
used off-label during PPH. Given the current lack of evidence to support their use in PPH, we 
do not recommend their use outside patients under dicumarinic treatment or clinical trials, 
because their side effects may outweigh their benefits.
9.5. Recombinant factor VIIa
Recombinant activated factor VII (rFVIIa) was developed for the treatment of hemophilia. It 
has been used off-label in life-threatening PPH or to prevent hysterectomy [35].
In a recent systematic review about the use of rFVIIa in severe PPH refractory to uterotonics, 
it was showed that rFVIIa reduce the need for specific second-line therapies in about 1 in 3 
patients, with the occurrence of nonfatal venous thrombotic events in 1 in 20 patients [36].
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The World Health Organization argues that it is not possible to reach meaningful conclusions 
from current literature [18] and clinical trials are needed (Table 6).
Unfortunately, blood transfusion has its own adverse consequences. To decrease transfusion 
exposure and to control the bleeding, pro-hemostatic agents are used more and more often in 
women with PPH.
9.6. Tranexamic acid
Tranexamic acid (TXA) is an antifibrinolytic agent that inhibits the activation of plasminogen 
into plasmin. It has been shown to reduce bleeding and transfusion requirement in massive 
hemorrhage secondary to a number of nonobstetric causes and it seems that is also effective 
in obstetric bleeding, decreasing the postpartum blood loss and preventing PPH and blood 
transfusions [10].
There appeared to be no increased risk of venous thromboembolism and no difference in 
length of hospital stay associated with TXA use. Although the prophylactic TXA administra-
tion may be associated with improved peripartum bleeding, existing evidence is insufficient 
for any definitive recommendations secondary to the poor to moderate quality of the litera-
ture [37].
The double-blinded WOMAN study [38] aims to investigate the role of TXA in early PPH. 
This study will provide valuable information on the role of early TXA in reducing progres-
sion from mild to severe PPH. There are other open studies to determinate the role of TXA 
as a complementary treatment of third stage of labor, in addition to prophylactic uterotonic 
drugs [39].
However, owing to its low cost and low rate of side effects, the use of TXA is currently recom-
mended by several academic societies. For example, the most recently updated PPH treat-
ment guidelines prepared by the World Health Organization state that TA (1 g over 5 min, 
repeated within 30–60 min if necessary) is recommended for the treatment of PPH if oxytocin 
and other uterotonics fail to stop bleeding or if it is thought that the bleeding may be partly 
due to trauma (weak recommendation) [40].
TXA is a promising candidate drug, inexpensive, easy to administer, and simple to add to the 
routine management of deliveries in hospitals.
Hemoglobin/hematocrit 9–10 g/dL/ 27–30%
Platelets >50,000
Fibrinogen 1.5–2 g/l
Ionic calcium Normocalcemia
Temperature >35°C
Table 6. Goals of transfusion for an obstetric patient.
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10. Etiologic treatment
10.1. Mechanical measures
The simple mechanical and physiological measures of ‘rubbing up the fundus’, bimanual uter-
ine compression, and emptying the bladder to stimulate uterine contraction represent the first-
line management of PPH. No published studies were identified to provide an evidence base 
for these interventions; nevertheless, professional consensus supports their continued use.
10.2. Uterotonic drugs
The use of uterotonics has a central role in the treatment of PPH. Treatment must be accompa-
nied by careful clinical examination to ascertain that the uterus is indeed atonic and that other 
sources of bleeding, such as genital tract lacerations or uterine inversion have been excluded.
10.2.1. Oxytocin
Intravenous oxytocin is the first-line uterotonic; this recommendation also covers women 
who have already received this drug for PPH prophylaxis [40]. When given as an intravenous 
bolus, the drug should be given slowly in a dose of not more than five units.
Easier methods for oxytocin administration have been developed for use in resource-poor set-
tings, but a systematic review fails to demonstrate that oxytocin administered by community 
health officers reduces the incidence of severe PPH (>1000 ml), severe maternal morbidity, or 
maternal deaths [41].
10.2.2. Ergometrine
In settings in which IV oxytocin is not available or if the bleeding does not respond to oxyto-
cin, ergometrine, oxytocin-ergometrine fixed dose, or a prostaglandin drug (including 800 μg 
of sublingual misoprostol) is considered a valid alternative.
10.2.3. Prostaglandin: carboprost and misoprostol
Carboprost (15 methylprostaglandin F2) was more effective than oxytocin in preventing PPH 
in high-risk patients undergoing cesarean delivery [42]. If the bleeding occurs at the time of 
cesarean section, intramyometrial injection of carboprost may be used.
The recommended dose is 250 μg intramuscularly. This may be repeated every 15 min to a total 
dose of 2 mg (eight doses). However, if significant atonic hemorrhage continues after a third 
dose of carboprost, without significant improvement (i.e., 30 min or more after the first dose 
was given), the team should consider transfer to the operating theater for examination under 
anesthesia, with an awareness of the impending need for laparotomy and/or hysterectomy.
Misoprostol (prostaglandin E1) is appropriate if carboprost is not indicated, as asthma patients 
or not available. A systematic review suggests that among women who received oxytocin for 
the treatment of primary PPH, adjunctive use of misoprostol confers no added benefit [43]. 
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Misoprostol does not appear to increase or reduce severe morbidity (excluding hyperpyrexia) 
when used to prevent or treat PPH, does not modify maternal mortality, but is associated 
with an increased risk of pyrexia, particularly in dosages of 600 μg or more. Therefore, it is 
recommended to use the lowest effective dose [44].
A study [45] of women in early pregnancy demonstrated that regardless of the route of 
administration (vaginal, sublingual, or rectal), misoprostol took 1.0–2.5 h to increase uterine 
tone. Clinicians should be aware of this delay in the clinical effect of misoprostol. Sublingual 
administration is recommended by WHO guidelines [40] (Table 7).
10.3. Surgical treatments
If pharmacological measures fail to control hemorrhage, surgical interventions should be ini-
tiated sooner than later. The most appropriate choice of treatment will depend, in part, on the 
team experience.
10.3.1. Uterine balloon tamponade
Intrauterine balloon tamponade has been suggested as an effective, easily administered mini-
mally invasive treatment option to control uterine bleeding while preserving the mother's 
ability to bear additional children [46]. In terms of mechanism of action, the intrauterine bal-
loon is believed to act by exerting inward to outward pressure against the uterine wall, result-
ing in a reduction in persistent capillary and venous bleeding from the endometrium and the 
myometrium [47].
Multiple types of balloons are available, including Bakri balloon, BT-cath balloon tamponade 
catheter, Foley catheters, Rusch balloon, condom catheters, and the Sengstaken-Blakemore 
tube. The Bakri postpartum balloon [48] and the BT-cath balloon tamponade catheter [49] 
are specifically designed for postpartum intrauterine tamponade. However, in settings where 
these are unavailable, other balloons can be used to achieve a similar effect.
Bakri balloon must be filled with 300–500 ml of sterile saline. There is no clear evidence on 
how long the tamponade should be left in place, but its effects can be observed after 4–6 h 
in most cases. In a small case series, success rates of uterine balloon catheters for controlling 
hemorrhage ranged from 57% after cesarean delivery to 100% after vaginal delivery [50, 51].
Balloon tamponade also allows maternal stabilization, necessary for embolization or for 
transfer to an intensive unit care.
10.3.2. Uterine hemostatic sutures
In recent years, uterine compression sutures, in particular B-Lynch suture, described in 1997 
[52] and Hayman suture [53], have been developed for ease and rapidity even in less expert 
hands. Both are considered easy-to-apply conservative techniques, regarding to reduce the 
arrival of blood from the uterine vessels to the bleeding zone. Sutures are allocated around the 
uterus with thick absorbable material causing contact and compression of the uterine anterior 
and posterior walls.
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Drug Dose Route of administration Frequency Secondary effects Caution/contraindication
Oxytocin IV Unusual: antidiuretic 
effect (cerebral or 
pulmonary edema) 
nausea, vomiting–quick 
infusion: hypotension, 
arrhythmia, stroke.
Syntocinon® 10–40 UI (Saline 0.9% 125 ml/h) Pneumopathy 
cardiopathy nephropathy 
hepatic disease
Ergometrine 10 UI IM/IMM Hypertension, 
cardiopathy or 
cardiovascular risk 
factor, nephropathy, 
liver disease, systemic 
infection
Methergine® 5 UI Bolus iv slow (3–5 min) /2–4 h (max. 5 doses) Hypertensive crisis, 
vasoconstriction, nausea, 
vomiting
Carboprost 0.2 mg IM Pneumopathy 
asthma), cardiopathy, 
nephropathy, severe liver 
disease.
-Cl related: HTA, 
glaucoma, bronchial 
asthma
-Epilepsy
(15-methyl PGF2α) 
Hemabate®
0.125 mg IMM /15–90 min max. 2 mg (8 
doses)
Bronchospasm diarrhea, 
nausea and vomiting 
hypertension or 
hypotension headache, 
flushing
Misoprostol (PGE1) 
Cytotec®
600–1000 μg Sublingual-rectal /2–6 h Fever
Diarrhea
Nausea and vomiting
Table 7. Uterotonic drugs.
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B-Lynch suture requires hysterotomy for its realization and in Hayman suture is not neces-
sary. Its overall efficacy ranged from 81 to 91.7% and gestations after its application have been 
described [50, 54].
Main complications include ischemia and uterine infection, especially in transverse sutures, 
because of difficulty to drain uterine contents, as in the case of the Cho technique. A risk of 
intestinal strangulation in the space between the suture and the uterus after the uterine invo-
lution must be awarded. Therefore, absorbable sutures should be used.
10.3.3. Pelvic artery embolization (PAE)
The largest study with 251 patients treated with arterial embolization observed that this tech-
nique is safe and effective for managing primary PPH. However, patients with disseminated 
intravascular coagulation and massive transfusion of more than 10 red blood cell units were 
more likely to have failed embolization [55].
PAE is found to be a minimally invasive, highly successful, and safe technique for the man-
agement of PPH in a recent systematic review of 21 studies, being successful in 89.4% of cases. 
The mortality rate was 0.9% and other major complications were uncommon (1.8%). It should 
be considered in PPH refractory to initial treatment [56].
Another recent systematic review, including 28 small studies about procedures, as embolization 
or uterine tamponade, or surgeries, arterial ligation or uterine compression sutures, concluded 
that given the insufficient evidence, clinicians must continue to make individual care decisions 
based on each woman’s clinical situation and available management options [57]. Some studies 
with longer term follow-up reported infertility in women undergoing embolization.
10.3.4. Artery ligation
Uterine artery ligation depends on gynecology expertise. It may include the terminal part of 
the uterine branch, a second lower suture involving cervical branches or mass ligation of the 
uterine arteries and veins, including part of the myometrium (O'Leary's suture) [58].
Effectiveness is between 40 and 100% can preserve the uterus and subsequent fertility and is 
simpler than the ligation of hypogastric arteries, although it is associated with an increased 
risk of ureteral injury.
Internal iliac artery ligation is technically more complicated. Opening of the peritoneum from 
the bifurcation of the iliac vessels, identifying and separating the ureter medially are required 
and then individualizing the internal iliac artery proceeding to the double ligation of its 
branch (about 2–3 cm from the bifurcation) without sectioning the vessel [59].
The efficacy of the technique is similar to uterine artery ligation, although it may also be used 
in cases of traumatic uterine injury or even after hysterectomy [60]. Possible complications are 
uterine necrosis, vascular perforation, and ureteral injury.
It should be borne in mind that it may hinder further embolization. Its complications include 
necrosis (rare), either uterine or other neighboring territories, vascular perforation (mainly 
iliac vein), and ureteral lesion.
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A systematic review [61] of fertility outcomes following the surgical management of PPH con-
cluded that uterine devascularisation techniques, including internal iliac artery ligation, did 
not adversely affect future fertility, although, the number of studies and quality of evidence 
were limited.
10.3.5. Hysterectomy
Hysterectomy is the most radical therapeutic option and definitively compromises fertility. 
The decision and procedure must be carried out by an experienced clinician and surgeon. 
It should not be considered a first-choice technique except in some situations, as placenta 
accreta or uterine rupture [62]. It is considered in case of failure of conservative techniques, 
but an excessive delay has to be avoided.
11. Use of protocols
Protocols should provide a standardized approach to evaluate and monitor the patients, involv-
ing a multi-professional team. The protocols must be founded on literature review according 
to evidence-based medicine. Each maternity unit should have its own protocol adapted to the 
particularities of its organization. The protocol must be able to respond to cases of major hem-
orrhage. The multi-professional team together with hematology and blood bank staff should 
update and test this protocol regularly. The protocol must be updated every few years with 
recent publications.
Summarizing protocols in algorithms improve its application. Algorithms reflected in post-
ers must be located at critical points of obstetric spaces for easy reference. Some publications 
[63, 64] show that the new application of a PPH protocol was associated with the resolution of 
maternal bleeding at an earlier stage or the use of fewer blood products.
There is a growing awareness of the importance of a checklist for assisting healthcare pro-
viders during medical crises. Checklists together with simulation training improve multi-
professional team performance. It is recommended to use a checklist reader: a person who 
reads out loud the checklist to the team leader. It has been observed that the checklist reader 
can decrease task saturation experienced by the team leader thereby, increasing the likelihood 
that all critical tasks are completed [65].
In obstetrics, the patient safety checklist has been promoted as an important tool for improving 
perinatal care and reducing maternal and neonatal mortality. The World Health Organization 
[66] has developed a 29-item checklist to promote the delivery of key maternal and perinatal 
care practice. The use of checklist could be a prospective way to help to do things or using it 
retrospectively, to verify if all points are done. However, it is necessary to standardize how 
teams use checklists during obstetric crises.
Poor team organization and task assignment have also been reported in a simulation study 
[67] of how physicians perform during simulated obstetric emergencies, including PPH. This 
shows the importance of effective communication among care providers during obstetric cri-
ses. Mistakes in communication are recognized as the root cause of many sentinel events on 
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the labor unit [68]. Accordingly, periodic training to improve and maintain effective commu-
nication between providers should be encouraged [69].
Goldhaber and Howard [70] proposed four elements for implementing a crisis checklist:
• To create or customize the checklist.
• To familiarize providers in using the checklist effectively.
• To use checklists in clinical practice.
• To integrate into a hospital safety culture.
Improving PPH recognition and response times along with improved team communica-
tion may significantly improve patient outcomes and decrease maternal mortality. The Joint 
Commission (JC) [68] has recommended team training and clinical drills for high-risk events 
including maternal hemorrhage. The JC report also emphasized the importance of team train-
ing and communication skills when it reported that communication issues were the root 
cause of perinatal death or permanent infant disability in 72% of cases.
A systematic review of multi-professional team simulation training with integrated acute 
obstetric training interventions in a simulation setting [71] is potentially effective in the pre-
vention of errors, thus improving patient safety in acute obstetric emergencies. Studies on its 
effectiveness and cost-effectiveness are needed before team training can be implemented on 
a broad scale.
In addition to a protocol and checklist, it is also useful to have a PPH emergency kit. This kit 
should include emergency equipment, treatment algorithms, and medications required for 
the immediate management of PPH.
Another tool that helps to early recognize bleeding is the modified early obstetric warning score 
(MEOWS) charts. The modified early obstetric warning score (MEOWS) has been designed to 
allow early recognition of physical deterioration in women by monitoring their physiologi-
cal parameters. MEOWS is a score attributed to these parameters and documented on the 
MEOWS observation chart [72]. It is believed that small changes in the combined physiological 
variables measured by MEOWS may pick up deterioration earlier than an obvious change in 
an individual variable. Early detection will trigger subsequent prompt intervention that will 
either reverse further physiological decline or facilitate timely referral to appropriate person-
nel. The use of an early warning score is also supported by NICE in the guideline ‘Acutely ill 
patients in hospital: recognition of and response to acute illness in adults in hospital’ [73].
12. Red code
PPH is a typical obstetric emergency that can develop rapidly and unexpectedly. In case of 
need, it is imperative to adopt an obstetric hemorrhage massive transfusion protocol (red 
protocol) for obstetric patients with massive hemorrhage and continued bleeding. This must 
be able to respond to the need to have blood products as soon as possible. In the red code 
activation, several key points are identified. Grating roles and developing an action algorithm 
Massive Postpartum Hemorrhage: Protocol and Red Code
http://dx.doi.org/10.5772/intechopen.69968
133
known for all team members (obstetricians, anesthesiologists, midwives, auxiliary staff, and 
laboratory blood bank staff) is the key to success.
The use of in situ simulation before the implementation of a new health care protocol can be 
useful to facilitate finding previously not valued critical points, allowing make changes before 
final application. Creation of PPH training drills has allowed identifying the most common 
mistakes. Some of them are:
• Underestimate the blood loss.
• Delay in recognition of the severity of the bleeding until the patients become shocked.
• Failure to promptly recognize concealed bleeding.
• Delay in starting adequate fluid resuscitation.
• Ignorance about how to access blood products rapidly.
In the case of the red code protocol, the use of simulation allowed to change the shipping and 
collecting sample circuit, improving time reception of first unit of blood. The active participa-
tion of the multidisciplinary team can provide point improvement in the proposed protocols 
and, subsequently, it can generate greater compliance with them.
However, maternity wards have relatively few opportunities to train by self-experience and 
to evaluate and discuss how previous cases have been managed. During any emergency situ-
ation, communication and organizing the process of care are difficult tasks. It has been rec-
ognized that in many cases there is no clear leadership [74], and poor teamwork has been 
recognized as a major cause of poor outcome [75].
The team training based on a simulation is effective because it allows a deeper analysis of 
knowledge, attitudes, and behavior in professional teams. This simulation methodology has 
shown to improve patient safety in acute obstetric emergencies [76].
Author details
Jaume Miñano Masip, Laura Almeida Toledano, Sílvia Ferrero Martínez and  
María Dolores Gómez Roig*
*Address all correspondence to: lgomezroig@sjdhospitalbarcelona.org
BCNatal Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Sant Joan de 
Déu, Barcelona, Spain
References
[1] Prevention and Management of Postpartum Haemorrhage: Green-top Guideline No. 
52. BJOG [Internet]. 2016 Dec 16 [cited 2017 Feb 21]. Available from: http://doi.wiley.
com/10.1111/1471-0528.14178
Obstetrics134
[2] Leduc D, Senikas V, Lalonde AB, Ballerman C, Biringer A, Delaney M, et al. Active man-
agement of the third stage of labour: Prevention and treatment of postpartum hemor-
rhage. Journal of Obstetrics Gynaecology Canada [Internet]. 2009 Oct [cited 2017 Feb 
21];31(10):980-993. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19941729
[3] World Health Organization. WHO Recommendations for the Prevention and Treatment 
of Postpartum Haemorrhage [Internet]. Geneva; 2012 [cited 2017 Feb 21]. Available 
from: www.who.int/maternal_child_adolescent
[4] Maternal Collapse in Pregnancy and the Puerperium. RCOG Green-top Guideline No. 
56. 2011
[5] Begley CM, Gyte GML, Devane D, McGuire W, Weeks A. Active versus expectant man-
agement for women in the third stage of labour. Begley CM, editor. Cochrane Database 
of Systematic Reviews [Internet]. 2015 Mar 2 [cited 2017 Feb 21];(3):CD007412. Available 
from: http://doi.wiley.com/10.1002/14651858.CD007412.pub4
[6] Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemor-
rhage. Su L-L, editor. Cochrane Database of Systematic Reviews [Internet]. 2007 Jul 18 
[cited 2017 Feb 21];(3):CD005457. Available from: http://doi.wiley.com/10.1002/14651858.
CD005457.pub2
[7] Su L-L, Chong Y-S, Samuel M. Carbetocin for preventing postpartum haemorrhage. 
Su L-L, editor. Cochrane database Syst Rev [Internet]. 2012 Apr 18 [cited 2017 Feb 
21];(4):CD005457. Available from: http://doi.wiley.com/10.1002/14651858.CD005457.pub4
[8] McDonald SJ, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin 
for the third stage of labour. In: McDonald SJ, editor. Cochrane Database of Systematic 
Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2004 [cited 2017 Feb 21]. p. 
CD000201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14973949
[9] Tunçalp Ö, Hofmeyr GJ, Gülmezoglu AM. Prostaglandins for preventing postpartum 
haemorrhage. In: Tunçalp Ö, editor. Cochrane Database of Systematic Reviews [Internet]. 
Chichester, UK: John Wiley & Sons, Ltd; 2012 [cited 2017 Feb 21]. p. CD000494. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/22895917
[10] Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haem-
orrhage. Novikova N, editor. Cochrane Database of Systematic Reviews [Internet]. 2015 
Jun 16 [cited 2017 Feb 21];(6):CD007872. Available from: http://doi.wiley.com/10.1002/ 
14651858.CD007872.pub3
[11] Hancock A, Weeks AD, Lavender DT. Is accurate and reliable blood loss estima-
tion the “crucial step” in early detection of postpartum haemorrhage: An integrative 
review of the literature. BMC Pregnancy Childbirth [Internet]. 2015 Sep 28 [cited 2017 
Feb 21];15(1):230. Available from: http://bmcpregnancychildbirth.biomedcentral.com/
articles/10.1186/s12884-015-0653-6
[12] Allard S, Green L, Hunt BJ. How we manage the haematological aspects of major obstet-
ric haemorrhage. British Journal of Haematology [Internet]. 2014 Jan [cited 2017 Feb 
21];164(2):177-188. Available from: http://doi.wiley.com/10.1111/bjh.12605
Massive Postpartum Hemorrhage: Protocol and Red Code
http://dx.doi.org/10.5772/intechopen.69968
135
[13] Collins PW, Lilley G, Bruynseels D, Laurent DB-S, Cannings-John R, Precious E, et al. 
Fibrin-based clot formation as an early and rapid biomarker for progression of post-
partum hemorrhage: a prospective study. Blood [Internet]. 2014 Sep 11 [cited 2017 Feb 
21];124(11):1727-1736. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/
blood-2014-04-567891
[14] Obstetric Anaesthetists' Association and Association of Anaesthetists of Great Britain & 
Ireland. http:// .aagbi.org/sites/default/files/obstetric_anaesthetic_services_2013.pdf
[15] Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, 
Filipescu DC, et al. Management of severe perioperative bleeding: Guidelines from the 
European Society of Anaesthesiology. European Journal of Anaesthesiology [Internet]. 
2013 Jun [cited 2017 Feb 21];30(6):270-382. Available from: http://content.wkhealth.com/
linkback/openurl?sid=WKPTLP:landingpage&an=00003643-201306000-00002
[16] American Society of Anesthesiologists Task Force on Perioperative Blood Management. 
Practice guidelines for perioperative blood management: An updated report by the 
American Society of Anesthesiologists Task Force on Perioperative Blood Management*. 
Anesthesiology [Internet]. 2015 Feb [cited 2017 Feb 21];122(2):241-275. Available from: http://
content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00000542- 
201502000-00012
[17] Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically 
ill patients. In: Perel P, editor. Cochrane Database of Systematic Reviews [Internet]. 
Chichester, UK: John Wiley & Sons, Ltd; 2013 [cited 2017 Feb 21]. Available from: http://
doi.wiley.com/10.1002/14651858.CD000567.pub6
[18] WHO Guidelines for the Management of Postpartum Haemorrhage and Retained 
Placenta. World Health Organization. Available from: http://apps.who.int/iris/bitstr
eam/10665/44171/1/9789241598514_eng.pdf
[19] Mehrabadi A, Hutcheon JA, Lee L, Kramer MS, Liston RM, Joseph KS. Epidemiological 
investigation of a temporal increase in atonic postpartum haemorrhage: A population-
based retrospective cohort study. BJOG [Internet]. 2013 Jun [cited 2017 Feb 21];120(7):853-
862. Available from: http://doi.wiley.com/10.1111/1471-0528.12149
[20] Callaghan WM, Grobman WA, Kilpatrick SJ, Main EK, DʼAlton M. Facility-based iden-
tification of women with severe maternal morbidity: It is time to start. Obstetrics and 
Gynecology [Internet]. 2014 May [cited 2017 Feb 21];123(5):978-981. Available from: http://
content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006250- 
201405000-00012
[21] British Committee for Standards in Haematology D, Stainsby D, MacLennan S, Thomas 
D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. British 
Journal of Haematology [Internet]. 2006 Dec [cited 2017 Feb 21];135(5):634-641. Available 
from: http://doi.wiley.com/10.1111/j.1365-2141.2006.06355.x
[22] Pasquier P, Gayat E, Rackelboom T, La Rosa J, Tashkandi A, Tesniere A, et al. An obser-
vational study of the fresh frozen plasma: Red blood cell ratio in postpartum hemor-
rhage. Anesthesia Analgesia [Internet]. 2013 Jan [cited 2017 Feb 21];116(1):155-161. 
Obstetrics136
Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingp
age&an=00000539-201301000-00019
[23] Bonnet MP, Benhamou D. Management of postpartum haemorrhage. F1000Research 
[Internet]. 2016 Jun 27 [cited 2017 Feb 21];5:1514. Available from: http://f1000research.
com/articles/5-1514/v1
[24] Association of Anaesthetists of Great Britain and Ireland, Thomas D, Wee M, Clyburn 
P, Walker I, Brohi K, et al. Blood transfusion and the anaesthetist: management of mas-
sive haemorrhage. Anaesthesia [Internet]. 2010 Nov [cited 2017 Feb 21];65(11):1153-1161. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20963925
[25] Clark SL. Obstetric hemorrhage. Seminars in Perinatology [Internet]. 2016;40(2):109-111. 
Available from: http://dx.doi.org/10.1053/j.semperi.2015.11.016
[26] Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz R-C, Bouvier-Colle M-H, 
et al. Association between fibrinogen level and severity of postpartum haemorrhage: 
Secondary analysis of a prospective trial. British Journal of Anaesthesia [Internet]. 2012 
Jun 1 [cited 2017 Feb 21];108(6):984-989. Available from: https://academic.oup.com/bja/
article-lookup/doi/10.1093/bja/aes096
[27] Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease 
of fibrinogen is an early predictor of the severity of postpartum hemorrhage. Journal 
of Thrombosis and Haemostasis [Internet]. 2007 Feb [cited 2017 Feb 21];5(2):266-273. 
Available from: http://doi.wiley.com/10.1111/j.1538-7836.2007.02297.x
[28] Glover NJ, Collis RE, Collins P. Fibrinogen concentrate use during major obstetric haem-
orrhage. Anaesthesia [Internet]. 2010 Dec [cited 2017 Feb 21];65(12):1229-1230. Available 
from: http://doi.wiley.com/10.1111/j.1365-2044.2010.06548.x
[29] Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S, Fanning R, et al. The efficacy of 
fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage—
An observational study. Transfusion Medicine [Internet]. 2012 Oct [cited 2017 Feb 
21];22(5):344-349. Available from: http://doi.wiley.com/10.1111/j.1365-3148.2012.01178.x
[30] Wikkelsø AJ, Edwards HM, Afshari A, Stensballe J, Langhoff-Roos J, Albrechtsen C, 
et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemor-
rhage: Randomized controlled trial. British Journal of Anaesthesia [Internet]. 2015 Apr 
1 [cited 2017 Feb 21];114(4):623-633. Available from: https://academic.oup.com/bja/
article-lookup/doi/10.1093/bja/aeu444
[31] Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for 
ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. 
Anaesthesia [Internet]. 2015 Feb [cited 2017 Feb 21];70(2):166-175. Available from: http://
doi.wiley.com/10.1111/anae.12859
[32] Wikkelsø A, Lunde J, Johansen M, Stensballe J, Wetterslev J, Møller AM, et al. Fibrinogen 
concentrate in bleeding patients. Wikkelsø A, editor. Cochrane Database of Systematic 
Reviews [Internet]. 2013 Aug 29 [cited 2017 Feb 21];(8):CD008864. Available from: http://
doi.wiley.com/10.1002/14651858.CD008864.pub2
Massive Postpartum Hemorrhage: Protocol and Red Code
http://dx.doi.org/10.5772/intechopen.69968
137
[33] Ducloy-Bouthors A-S, Mignon A, Huissoud C, Grouin J-M, Mercier FJ. Fibrinogen con-
centrate as a treatment for postpartum haemorrhage-induced coagulopathy: A study 
protocol for a randomised multicentre controlled trial. The fibrinogen in haemorrhage 
of DELivery (FIDEL) trial. Anaesthesia, Critical Care and Pain Medicine [Internet]. 2016 
Aug [cited 2017 Feb 21];35(4):293-298. Available from: http://linkinghub.elsevier.com/
retrieve/pii/S2352556816300169
[34] Aawar N, Alikhan R, Bruynseels D, Cannings-John R, Collis R, Dick J, et al. Fibrinogen 
concentrate versus placebo for treatment of postpartum haemorrhage: Study protocol for 
a randomised controlled trial. Trials [Internet]. 2015 Dec 17 [cited 2017 Feb 21];16(1):169. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/25906770
[35] James AH, McLintock C, Lockhart E. Postpartum hemorrhage: when uterotonics and 
sutures fail. American Journal of Hematology [Internet]. 2012 May [cited 2017 Feb 21];87 
Suppl 1(S1):S16-S22. Available from: http://doi.wiley.com/10.1002/ajh.23156
[36] Lavigne-Lissalde G, Aya AG, Mercier FJ, Roger-Christoph S, Chauleur C, Morau E, et 
al. Recombinant human FVIIa for reducing the need for invasive second-line therapies 
in severe refractory postpartum hemorrhage: A multicenter, randomized, open con-
trolled trial. Journal of Thrombosis and Haemostasis [Internet]. 2015 Apr [cited 2017 Feb 
21];13(4):520-529. Available from: http://doi.wiley.com/10.1111/jth.12844
[37] Alam A, Choi S. Prophylactic use of tranexamic acid for postpartum bleeding outcomes: 
A systematic review and meta-analysis of randomized controlled trials. Transfusion 
Medical Reviews [Internet]. 2015 Oct [cited 2017 Feb 21];29(4):231-241. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0887796315000747
[38] Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, et al. The 
WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treat-
ment of postpartum haemorrhage: An international randomised, double blind placebo 
controlled trial. Trials [Internet]. 2010 Apr 16 [cited 2017 Feb 21];11(1):40. Available from: 
http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-11-40
[39] Sentilhes L, Daniel V, Darsonval A, Deruelle P, Vardon D, Perrotin F, et al. Study protocol. 
TRAAP—TRAnexamic Acid for Preventing postpartum hemorrhage after vaginal deliv-
ery: A multicenter randomized, double-blind, placebo-controlled trial. BMC Pregnancy 
Childbirth [Internet]. 2015 Jun 14 [cited 2017 Feb 21];15(1):135. Available from: http://
bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-015-0573-5
[40] Tunçalp O, Souza JP, Gülmezoglu M, World Health Organization. New WHO recom-
mendations on prevention and treatment of postpartum hemorrhage. International 
Journal of Gynaecology and Obstetrics [Internet]. 2013 Dec [cited 2017 Feb 21];123(3):254-
256. Available from: http://doi.wiley.com/10.1016/j.ijgo.2013.06.024
[41] Pantoja T, Abalos E, Chapman E, Vera C, Serrano VP. Oxytocin for preventing post-
partum haemorrhage (PPH) in non-facility birth settings. Pantoja T, editor. Cochrane 
Database of Systematic Reviews [Internet]. 2016 Apr 14 [cited 2017 Feb 21];4:CD011491. 
Available from: http://doi.wiley.com/10.1002/14651858.CD011491.pub2
Obstetrics138
[42] Bai J, Sun Q, Zhai H. A comparison of oxytocin and carboprost tromethamine in the pre-
vention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery. 
Experimental and Therapeutic Medicine [Internet]. 2014 Jan 1 [cited 2017 Feb 21];7(1):46-
50. Available from: http://www.spandidos-publications.com/10.3892/etm.2013.1379
[43] Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment for primary 
postpartum haemorrhage. Mousa HA, editor. Cochrane Database of Systematic Reviews 
[Internet]. 2014 Feb 13 [cited 2017 Feb 21];(2):CD003249. Available from: http://doi.wiley.
com/10.1002/14651858.CD003249.pub3
[44] Hofmeyr GJ, Gülmezoglu AM, Novikova N, Lawrie TA. Postpartum misoprostol for 
preventing maternal mortality and morbidity. Hofmeyr GJ, editor. Cochrane Database 
of Systematic Reviews [Internet]. 2013 Jul 15 [cited 2017 Feb 21];(7):CD008982. Available 
from: http://doi.wiley.com/10.1002/14651858.CD008982.pub2
[45] Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol 
administered by epithelial routes: Drug absorption and uterine response. Obstetrics 
and Gynecology [Internet]. 2006 Sep [cited 2017 Feb 21];108(3 Pt 1):582-590. Available 
from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage
&an=00006250-200609000-00017
[46] Lo A, St Marie P, Yadav P, Belisle E, Markenson G. The impact of Bakri balloon tampon-
ade on the rate of postpartum hysterectomy for uterine atony. The Journal of Maternal 
Fetal Neonatal Medicine [Internet]. 2016 Jul 29 [cited 2017 Feb 21];1-4. Available from: 
http://www.tandfonline.com/doi/full/10.1080/14767058.2016.1208742
[47] Aggarwal N. The “tamponade test” in the management of massive postpartum hem-
orrhage. Obstetrics and Gynecology [Internet]. 2003 Sep [cited 2017 Feb 21];102(3):641; 
author reply 641-2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12962955
[48] Bakri Balloon Placement: Background, Indications, Contraindications [Internet]. [cited 
2017 Feb 21]. Available from: http://emedicine.medscape.com/article/2047283-overview
[49] BT-CATH Trademark of Utah Medical Products, Inc. Serial Number: 76693715 :: 
Trademarkia Trademarks [Internet]. [cited 2017 Feb 21]. Available from: http://www.
trademarkia.com/btcath-76693715.html
[50] Doumouchtsis SK, Papageorghiou AT, Arulkumaran S. Systematic review of conserva-
tive management of postpartum hemorrhage: what to do when medical treatment fails. 
Obstetrical and Gynecological Survey [Internet]. 2007 Aug [cited 2017 Feb 21];62(8):540-
547. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landi
ngpage&an=00006254-200708000-00023
[51] Vintejoux E, Ulrich D, Mousty E, Masia F, Marès P, de Tayrac R, et al. Success factors for 
BakriTM balloon usage secondary to uterine atony: A retrospective, multicentre study. 
The Australian and New Zealand Journal of Obstetrics and Gynaecology [Internet]. 
2015 Dec [cited 2017 Feb 21];55(6):572-577. Available from: http://doi.wiley.com/10.1111/
ajo.12376
Massive Postpartum Hemorrhage: Protocol and Red Code
http://dx.doi.org/10.5772/intechopen.69968
139
[52] B-Lynch C, Coker A, Lawal AH, Abu J, Cowen MJ. The B-Lynch surgical technique for the 
control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases 
reported. British Journal of Obstetrics and Gynaecoloy [Internet]. 1997 Mar [cited 2017 
Feb 21];104(3):372-375. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9091019
[53] Hayman RG, Arulkumaran S, Steer PJ. Uterine compression sutures: Surgical man-
agement of postpartum hemorrhage. Obstetrics and Gynecology [Internet]. 2002 
Mar [cited 2017 Feb 21];99(3):502-506. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/11864681
[54] Penney G, Brace V. Near miss audit in obstetrics. Current Opinion in Obstetrics and 
Gynecology [Internet]. 2007 Apr [cited 2017 Feb 21];19(2):145-150. Available from: http://
content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00001703- 
200704000-00009
[55] Lee HY, Shin JH, Kim J, Yoon H-K, Ko G-Y, Won H-S, et al. Primary postpartum hem-
orrhage: outcome of pelvic arterial embolization in 251 patients at a single institution. 
Radiology [Internet]. 2012 Sep [cited 2017 Feb 21];264(3):903-909. Available from: http://
pubs.rsna.org/doi/10.1148/radiol.12111383
[56] Ruiz Labarta FJ, Pintado Recarte MP, Alvarez Luque A, Joigneau Prieto L, Perez Martín 
L, Gonzalez Leyte M, et al. Outcomes of pelvic arterial embolization in the manage-
ment of postpartum haemorrhage: a case series study and systematic review. European 
Journal of Obstetrics and Gynecology and Reproductive Biology [Internet]. 2016 Nov 
[cited 2017 Feb 21];206:12-21. Available from: http://linkinghub.elsevier.com/retrieve/
pii/S0301211516308429
[57] Sathe NA, Likis FE, Young JL, Morgans A, Carlson-Bremer D, Andrews J. Procedures and uter-
ine-sparing surgeries for managing postpartum hemorrhage. Obstetrical and Gynecological 
Survey [Internet]. 2016 Feb [cited 2017 Feb 21];71(2):99-113. Available from: http://
content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006254- 
201602000-00019
[58] O'Leary JA. Uterine artery ligation in the control of postcesarean hemorrhage. Journal of 
Reproductive Medicine [Internet]. 1995 Mar [cited 2017 Feb 21];40(3):189-193. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/7776302
[59] Resch B, Sergent F, Blanc S, Baron M, Sentilhes L, Trichot C, et al. How I perform…hypo-
gastric artery ligation for postpartum haemorrhage. Gynecologie Obstetrique Fertilite 
[Internet]. 2008 Jan [cited 2017 Feb 21];36(1):85-87. Available from: http://linkinghub.
elsevier.com/retrieve/pii/S1297958907004948
[60] Joshi V, Otiv S, Majumder R, Nikam Y, Shrivastava M. Internal iliac artery ligation for 
arresting postpartum haemorrhage. BJOG An International Journal of Obstetrics and 
Gynaecology [Internet]. 2007 Jan 25 [cited 2017 Feb 21];114(3):356-361. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17261120
[61] Doumouchtsis SK, Nikolopoulos K, Talaulikar V, Krishna A, Arulkumaran S. Menstrual 
and fertility outcomes following the surgical management of postpartum haemorrhage: 
Obstetrics140
A systematic review. BJOG [Internet]. 2014 Mar [cited 2017 Feb 21];121(4):382-388. 
Available from: http://doi.wiley.com/10.1111/1471-0528.12546
[62] Placenta Praevia, Placenta Praevia Accreta and Vasa Praevia: Diagnosis and Management. 
Green–top Guideline No. 27. RCOG 2011. Available from: https://www.rcog.org.uk/glo-
balassets/documents/guidelines/gtg_27.pdf
[63] Rizvi F, Mackey R, Barrett T, McKenna P, Geary M. Successful reduction of massive 
postpartum haemorrhage by use of guidelines and staff education. BJOG [Internet]. 2004 
May [cited 2017 Feb 21];111(5):495-498. Available from: http://doi.wiley.com/10.1111/ 
j.1471-0528.2004.00103.x
[64] Shields LE, Wiesner S, Fulton J, Pelletreau B. Comprehensive maternal hemorrhage pro-
tocols reduce the use of blood products and improve patient safety. American Journal 
of Obstetrics and Gynecology [Internet]. 2015 Mar [cited 2017 Feb 21];212(3):272-280. 
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002937814006942
[65] Hilton G, Daniels K, Goldhaber-Fiebert SN, Lipman S, Carvalho B, Butwick A. Checklists 
and multidisciplinary team performance during simulated obstetric hemorrhage. 
International Journal of Obstetric Anesthesia [Internet]. 2016 Feb [cited 2017 Feb 21];25:9-
16. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0959289X15001223
[66] Spector JM, Lashoher A, Agrawal P, Lemer C, Dziekan G, Bahl R, et al. Designing 
the WHO Safe Childbirth Checklist program to improve quality of care at childbirth. 
International Journal of Gynaecology and Obstetrics [Internet]. 2013 Aug [cited 2017 Feb 
21];122(2):164-168. Available from: http://doi.wiley.com/10.1016/j.ijgo.2013.03.022
[67] Maslovitz S, Barkai G, Lessing JB, Ziv A, Many A. Recurrent obstetric management mis-
takes identified by simulation. Obstetrics and Gynecology [Internet]. 2007 Jun [cited 
2017 Feb 21];109(6):1295-1300. Available from: http://content.wkhealth.com/linkback/
openurl?sid=WKPTLP:landingpage&an=00006250-200706000-00008
[68] Sentinel Event Alert Issue 30—July 21, 2004. Preventing infant death and injury during 
delivery. Advances in Neonatal Care [Internet]. 2004 Aug [cited 2017 Feb 21];4(4):180-
181. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15368207
[69] Siassakos D, Bristowe K, Hambly H, Angouri J, Crofts JF, Winter C, et al. Team com-
munication with patient actors: Findings from a multisite simulation study. Simulation 
in Healthcare [Internet]. 2011 Jun [cited 2017 Feb 21];6(3):143-149. Available from: http://
content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01266021- 
201106000-00003
[70] Goldhaber-Fiebert SN, Howard SK. Implementing emergency manuals: Can cognitive 
aids help translate best practices for patient care during acute events? Anesthesia and 
Analgesia [Internet]. 2013 Nov [cited 2017 Feb 21];117(5):1149-1161. Available from: http://
content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00000539- 
201311000-00018
[71] Merién AER, van de Ven J, Mol BW, Houterman S, Oei SG. Multidisciplinary team 
training in a simulation setting for acute obstetric emergencies: A systematic review. 
Massive Postpartum Hemorrhage: Protocol and Red Code
http://dx.doi.org/10.5772/intechopen.69968
141
Obstetrics and Gynecology [Internet]. 2010 May [cited 2017 Feb 21];115(5):1021-1031. 
Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpa
ge&an=00006250-201005000-00023
[72] Daisy N, Consultant Obstetrician & Gynaecologist, Rosie Goodsell PDM. Rosie Goodsell, 
Practice Development Midwife [Internet]. Clinical Guideline for: The use of the Modified 
Early Obstetric Warning Score (MEOWS) Author/s. 2016. pp. 1-9. Available from: 
file:///Users/Jaume/Downloads/Modified-Early-Obstetric-Warning-Score--MEOWS-- 
MID33---AO13-v4.1.pdf
[73] Rainey H, Ehrich K, Mackintosh N, Sandall J. The role of patients and their relatives 
in “speaking up” about their own safety—A qualitative study of acute illness. Health 
Expectations [Internet]. 2015 Jun [cited 2017 Feb 21];18(3):392-405. Available from: http://
doi.wiley.com/10.1111/hex.12044
[74] Guise J-M, Segel SY, Larison K, Jump SM, Constable M, Li H, et al. STORC safety ini-
tiative: A multicentre survey on preparedness & confidence in obstetric emergencies. 
Quality and Safety in Health Care [Internet]. 2010 Dec 1 [cited 2017 Feb 21];19(6):e41. 
Available from: http://qualitysafety.bmj.com/lookup/doi/10.1136/qshc.2008.030890
[75] Mazzocco K, Petitti DB, Fong KT, Bonacum D, Brookey J, Graham S, et al. Surgical 
team behaviors and patient outcomes. The American Journal of Surgery [Internet]. 2009 
May [cited 2017 Feb 21];197(5):678-685. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/18789425
[76] Draycott T, Sibanda T, Owen L, Akande V, Winter C, Reading S, et al. Does training 
in obstetric emergencies improve neonatal outcome? BJOG An International Journal 
of Obstetrics and Gynaecology [Internet]. 2006 Feb [cited 2017 Feb 21];113(2):177-182. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/16411995
Obstetrics142
